Date: 2014-07-08
Type of information: Collaboration agreement
Compound: drug discovery platform for genetic forms of epilepsy
Company: Epilepsy Foundation (USA), Intellimedix (USA - GA) Pfizer (USA - NY)
Therapeutic area: CNS diseases - Genetic diseases - Neurological diseases
Type agreement: collaboration R&D
Action mechanism:
Disease: epilepsy, Dravet syndrome
Details: * On July 8, 2014, the Epilepsy Foundation announced that the foundation is developing a drug discovery platform for genetic forms of epilepsy in collaboration with Intellimedix and Pfizer. The platform may help create individualized and potential new treatments for people living with Dravet Syndrome (a very severe type of genetic epilepsy) and other types of epilepsy for which limited treatment options are currently available.
Financial terms:
Latest news:
